

# Corrigendum to: Expert Consensus on the Use of a New Bioengineered, Cell-Friendly, Smooth Surface Breast Implant

Marcos Sforza, MD; Dennis C. Hammond, MD; Giovanni Botti, MD; Per Hedén, MD, PhD; Manuel Chacón Quirós, MD; Alexandre Mendonça Munhoz, MD, PhD; Brian M. Kinney, MD; and Niamh Corduff, MD

Aesthetic Surgery Journal  
2021, Vol 41(9) 1106

© 2019 The Aesthetic Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits

non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)

DOI: 10.1093/asj/sjz125

[www.aestheticsurgeryjournal.com](http://www.aestheticsurgeryjournal.com)

**OXFORD**  
UNIVERSITY PRESS

Corrigendum to “Expert Consensus on the Use of a New Bioengineered, Cell-Friendly, Smooth Surface Breast Implant” *Aesthet Surg J.* 2019;39(Supplement\_3):S95–S102; DOI: <https://doi.org/10.1093/asj/sjz054>.

After *Aesthetic Surgery Journal* was alerted to July 13 and 16, 2018 Establishment Labs Holdings, Inc. (Alajuela, San Jose, Costa Rica) correspondence with the Securities and Exchange Commission, the authors’ disclosures have now been amended, to wit: Dr. Sforza serves as coordinator of the Medical Advisory Board (MAB), has a consulting agreement with Establishment Labs Holdings, Inc., is a US clinical trial investigator, has received an option grant in September 2016 for 36,953 Class A Ordinary Shares and a restricted share grant in April 2018 for 68,233 Class A Ordinary Shares in Establishment Labs Holdings, and the author’s institution on April 17, 2014 entered into a Supply Agreement with Establishment Labs Holdings, Inc. Dr. Hammond has consulting agreements with Mentor Corporation (Santa Barbara, CA), the Musculoskeletal Transplant Foundation (Edison, NJ), Establishment Labs Holdings, Inc., and Nova Plasma Ltd. (Kibbutz Megiddo, Israel); receives book royalties from Elsevier (Amsterdam, the Netherlands); is a member of the

MAB at Establishment Labs Holdings, Inc; has a development agreement, including royalties for future products, has shares in Establishment Labs Holdings, Inc., and is also an investigator in Establishment Labs Holdings, Inc.’s US clinical trial. Dr. Botti declared no potential conflicts of interest with respect to the research, authorship, and publication of this article. Dr. Hedén has consulting agreements with Establishment Labs Holdings, Inc., Allergan (Dublin, Ireland), and Mentor, has shares in Establishment Labs Holdings, Inc., and is also an investigator in Establishment Labs Holdings, Inc.’s US clinical trial. Dr. Chacón-Quirós is a member of the MAB and consultant for Establishment Labs Holdings, Inc., and has shares in Establishment Labs Holdings, Inc. Dr. Munhoz is a member of the MAB at Establishment Labs Holdings, Inc., and has shares in Establishment Labs Holdings, Inc. Dr. Kinney is a member of the Scientific Advisory Board at Establishment Labs Holdings, Inc., and has shares in Establishment Labs Holdings, Inc., and is also an investigator in Establishment Labs Holdings, Inc.’s US clinical trial. Dr. Corduff has a consulting agreement with Establishment Labs Holdings, Inc., is a member of the MAB and has shares in Establishment Labs Holdings, Inc.